What is the management protocol for neonatal seizures?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management Protocol for Neonatal Seizures

Phenobarbital is the first-line treatment for neonatal seizures at a loading dose of 20 mg/kg IV, regardless of seizure etiology. 1, 2

Initial Assessment and Stabilization

  • Assess circulation, airway, and breathing (CAB) and provide appropriate airway protection 3
  • Administer high-flow oxygen to prevent hypoxia 3
  • Check blood glucose level immediately to rule out hypoglycemia as a potential cause 3
  • Initiate continuous EEG monitoring to confirm seizures and monitor response to treatment 1, 2

First-Line Treatment

  • Administer phenobarbital 20 mg/kg IV loading dose 1, 2
  • This dose typically achieves therapeutic plasma levels (15-30 μg/mL) within minutes of injection 4
  • If seizures persist after 20 minutes, consider giving an additional 10 mg/kg dose of phenobarbital (maximum total loading dose: 40 mg/kg) 2

Second-Line Treatment (if seizures persist after phenobarbital)

  • Options include (in order of preference):
    • Levetiracetam 40-60 mg/kg IV (preferred in neonates with cardiac disorders) 1, 2
    • Fosphenytoin/phenytoin 15-20 mg/kg IV (consider as first-line if channelopathy is suspected) 2, 5
    • Midazolam 0.1-0.2 mg/kg IV bolus followed by continuous infusion (0.1-0.4 mg/kg/hour) 1, 2
    • Lidocaine (if available) 2 mg/kg IV bolus followed by continuous infusion (4-6 mg/kg/hour) 1, 2

Third-Line Treatment (for refractory seizures)

  • Consider continuous midazolam infusion with escalating doses 1
  • For suspected vitamin B6-dependent epilepsy with seizures unresponsive to second-line ASMs, attempt a trial of pyridoxine 2
  • Consider consultation with pediatric neurology for further management 2

Maintenance Therapy

  • After seizure control is achieved, maintain phenobarbital at 3-4 mg/kg/day divided into 1-2 doses 4
  • Due to long half-life (69-165 hours), monitor for drug accumulation; avoid exceeding 5 mg/kg/day 4

Duration of Treatment

  • For acute symptomatic seizures without evidence of neonatal-onset epilepsy, discontinue antiseizure medications before discharge home 2
  • Early discontinuation after 1-2 weeks is generally possible 4
  • This recommendation applies regardless of MRI or EEG findings 2

Special Considerations

  • Therapeutic hypothermia may reduce seizure burden in neonates with hypoxic-ischemic encephalopathy 2
  • Treating electrographic-only seizures to achieve lower seizure burden may improve outcomes 2
  • For neonates requiring muscle relaxants, administer phenobarbital before curare to enable more effective mechanical ventilation 4

Important Caveats

  • Despite being the standard first-line treatment, phenobarbital controls seizures in fewer than half of neonates (43-45%) 5
  • The severity of seizures is a stronger predictor of treatment success than the specific medication used 5
  • Continuous EEG monitoring is essential to confirm seizure control, as clinical assessment alone is unreliable 1, 2
  • Withdrawal-associated seizures in neonates are primarily myoclonic, respond to opiates, and carry no increased long-term risk of poor outcomes 6

References

Guideline

Management of Status Epilepticus in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Phenobarbital in newborn infants. Overview].

Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde, 1984

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.